Ms Bowler faced four sets of charges, each of which contained sub-charges, summarised as follows:
Despite being served with the Notice of Inquiry, Ms Bowler decided not to attend the hearing due to ill-health but was represented by a counsel and solicitors.
The Committee did not find that Ms Bowler was medically unfit to attend on the basis of the medical evidence before it.
The Committee also concluded that it was in the public interest and interests of Ms Bowler to proceed with the hearing in her absence so that it could be concluded in a timely manner.
Ms Bowler’s counsel applied for parts of the hearing to be heard in private on health grounds, which was approved by the Committee.
It was also determined that any parts in the Committee’s decision or hearing that referred to Ms Bowler’s health would be redacted.
At the outset of the hearing, Ms Bowler’s counsel made admissions to five of the sub-charges which the Committee therefore found proven.
She also made some partial admissions in relations to a further 11 sub-charges.
After hearing a wide range of evidence, both written and oral, from Ms Bowler, the College, from clients and from an expert witness, the Committee found all charges proved except for four sub-charges.
On deciding whether the proved charges amounted to serious professional misconduct, the Committee took the following aggravating factors into account.
In mitigation:
In all, the Committee decided that the seriousness of the misconduct meant that a sanction was necessary to meet the public interest.
When deciding on whether to issue a reprimand with or without a warning, the Committee once again decided that the misconduct was too serious to allow for this.
It also decided that a reprimand and/or warning was not sufficient to protect animals and the wider public interest.
It then went onto consider whether a sanction of ‘suspension’ was sufficient but noted that it did not have enough evidence to show that Ms Bowler had shown significant insight to continue to practise unrestricted in the future.
The Committee eventually concluded that Ms Bowler’s conduct was incompatible with remaining on the Register.
Neil Slater, chairing the Disciplinary Committee and speaking on its behalf, said: “The Committee decided that the broad range of Ms Bowler’s misconduct which had spanned three years and eight months and involving injury or risk of injury to 18 animals, was incompatible with remaining on the Register and the public interest required removal from the Register even when all of Ms Bowler’s mitigation was taken into account.
“The Committee decided that it did not have sufficient evidence overall on Ms Bowler’s insight, current competence and future risk to persuade it that the lesser sanction of suspension was appropriate in this case.
“Although Ms Bowler had shown some insight, the Committee decided that she would need to have provided detailed evidence about her current practice before it could decide that she no longer represented a risk to animals in the future.
“The Committee therefore concluded that ‘removal from the Register’ was the appropriate and proportionate sanction because there had been a serious departure from professional standards, a reckless disregard for professional standards, multiple cases involving harm or risk of harm to animals and because, in Ms Bowler’s absence, it had been difficult to unravel whether she had an attitudinal problem.
“These were all factors in the Disciplinary Committee Sanctions Guidance that indicated that a sanction of removal was the appropriate sanction and, in the Committee’s decision, removal from the Register was the only sanction which would meet the public interest.
"It concluded that a lesser sanction would undermine public confidence in the profession and in the regulatory process.”
https://www.rcvs.org.uk/concerns/disciplinary-hearings
The update includes a new scoring system of low, moderate or high cancer risk which replaces the original numerical HDI scores and simplifies interpretation for clinicians, making the screening process easier to communicate with pet owners.
HT Vista says the device can now categorise cancer risk levels, based on malignant probability, with a sensitivity of 90% and a negative predictive value (NPV) of 98%.
The company says this translates to a “low cancer risk” result having a malignant probability of 10% or less, allowing veterinary teams to rule out cancer of lumps and bumps without the need for invasive procedures.
The tool can also now provide alerts for some of the low-risk cases, identifying them as lipomas, sebaceus adenomas or benign epithelial masses.
Liron Levy-Hirsch DVM MRCVS, Managing Director at HT Vista, said: "I am incredibly excited to enhance our already powerful HT Vista screening tool with a new diagnostic capability, providing veterinary teams with an even more comprehensive decision-support system.
"Our screening technology has already been a game-changer in early detection, and now, with the ability to flag specific tumour types, we are taking another significant step forward.
"This advancement empowers veterinary professionals to make even more informed decisions, supports shared decision-making with pet owners, and ultimately improves patient outcomes.
"By reducing the time from suspicion to diagnosis and treatment, we can detect cancer earlier, avoid the ‘wait and see’ approach, and help save more lives."
On the other end of the scale, a “high cancer risk” result has a malignant probability of 50% or more and indicates a stronger likelihood of malignancy.
HT Vista says these cases require additional diagnostic tests for mass identification.
The company highlights a big distinction between this and other screening modalities is that it can be nurse-led.
HT Vista will be on display and there will be live demonstrations at BSAVA Congress from the 20th to the 22nd of March 2025.
https://bit.ly/ht-vista-screening-tool
The device emits low dose 265 nanometre (nm) ultraviolet C light at a targeted area.
In a 2022 in vitro / ex vivo study to evaluate the therapeutic potential of 265nm UVC for infectious keratitis1, UVC was found to inhibit all tested bacteria and fungi, including mixed culture and strains linked to antibiotic resistance.
In the study, no evidence of infection was found from 4 hours onwards, ulcers responded significantly in under 24 hours, and at the end point, those treated with UVC performed as as well as those treated with ciprofloxacin.
Photon Therapeutics says that in simple cases, one five-second treatment will suffice, but more complex cases can be re-treated after 24 hours.
Currently, there are two main barriers to the successful treatment of eye infections in dogs.
The first is the difficulty diagnosing the infection and identifying the right antimicrobial to use, highlighted by a 2017 study: Bacterial Isolates from Canine External Ocular Disease and their Antimicrobial Sensitivities 2.
The second is whether the owner is able or willing to administer a topical treatment.
Here the evidence suggests that even when treatment is possible, people do not comply with clinical advice anything like as much as they claim.
Photon Therapeutics points to what it says is the nearest study there is, in which carers of young children with uveitis did not give the correct treatment in 75% of cases3.
If the device is as effective as claimed, then both these issues simply evaporate.
PhotonUVC costs £4,995.
https://photon-therapeutics.com
VetSurgeon.org product briefing: https://www.vetsurgeon.org/m/veterinary-product-briefing/138134
References
The updated indications reflect the recognition that Stelfonta may be used in any case where surgery may not be an option:
For the treatment of non-metastatic (WHO staging) mast cell tumours that are either non-resectable or those that are resectable but where surgery is not considered the best option, specifically: cutaneous mast cell tumours (located anywhere on the dog) and subcutaneous mast cell tumours located at or distal to the elbow or the hock.
Tumours must be less than or equal to 8 cm 3 in volume, and must be accessible to intratumoral injection.
Neil Mottram MRCVS, Technical Manager at Virbac said: “Stelfonta offers veterinary surgeons a medical option for the successful elimination of mast cell tumours.
"The extended labelled indication demonstrates the wide variety of cases that can benefit where medical treatment is preferred, such as; tumour factors (location and size) making surgical margins difficult, patient factors (concurrent disease and risk of anaesthesia), clinic factors and the simplification of this medical treatment and owner factors, where there is a preference to avoid surgery."
Stelfonta is administered by injection directly into the tumour mass and Virbac say that generally, dogs do not require sedation or local or general anaesthesia during treatment.
The active ingredient, Tigilanol tiglate, works largely through specific protein kinase c (PKC) activation, in which it locally stimulates the immune system, resulting in destruction of the tumour and the tumour’s blood supply, followed by rapid healing of the site with minimal scarring.
www.virbac.co.uk
The webinar is being presented by Cassie Woods (RVN Cons) CertNCS, Equine Nurse and Partner at Lower House Equine Clinic in Shropshire.
Cassie has a degree in bio-veterinary science and many years experience working in equine and small animal practice.
She regularly lectures for BVNA and BEVA. She is a member of the BEVA equine nurse committee and works closely with the BEVA Trust.
Cassie will share insights and practical strategies to strengthen biosecurity for both clinic and ambulatory teams, and will offer advice and guidance for helping clients to improve their own biosecurity measures.
Horiba's Veterinary specialists will also be available to answer veterinary diagnostics-related questions and share information about the range of pathogen tests the company offers.
https://horiba.link/register-143bbc
Photo: www.depositphotos.com
Tim, who is Managing Partner of Larkmead Vets and also a Director at the independent veterinary community XLVets, graduated from Liverpool Vet School in 1994 and joined Larkmead Vets in 1998.
He said: “I grew up in the South Yorkshire coalfields and worked in a city centre small animal practice in Wakefield before relocating to Oxfordshire to develop the small animal department of a mixed practice.
"First-opinion veterinary practice has been my life since starting cleaning kennels aged 12.
“I am passionate that whilst what we do is work with animals, how we do it is by working with people: our colleagues and the owners who entrust their animals to our care.
"As a first-opinion vet and practice owner I have had the privilege of growing and developing my practice (team and facilities) to meet the changing needs of our local community.
“At a time of great change for the veterinary profession, with the tantalising hope for a new Veterinary Surgeons Act set against the backdrop of the Competition and Markets Authority’s market investigation of the veterinary sector, it is an opportunity to bring this experience to the heart of our College.
“It was an unexpected honour to be elected to the position of JVP and I thank my colleagues on Council for entrusting the role to me.
"I also reflect on my initial university application which saw a clean sweep of rejections and hope that this can inspire others from the grass roots of our profession to get involved in shaping the future.”
Council also voted to confirm Professor Tim Parkin as RCVS President, Linda Belton as Senior Vice-President and reconfirmed Tshidi Gardiner as Treasurer (subject to her re-election), all effective from July.
Tim will take up his post at the College's AGM in July.
Led by Navaratnam Partheeban (Theeb) (pictured) OBE, Regional Head of Farm at IVC Evidensia, the programme is based on a methodology developed in the Netherlands.
The training focuses on the main behavioural indicators in cattle, helping vets and farmers assess health and welfare using basic senses such as looking, smelling, and feeling.
The one-day course includes a morning theory session followed by an on-farm practical session, equipping participants with skills to spot early signs of health or welfare issues before they become serious.
Theeb said: "Our goal is to train all our farm vets and vet techs in this approach, so they can provide even greater support to farmers.
"By integrating cow signals into routine practice, we can help farmers improve herd welfare, increase productivity, and contribute to more sustainable farming.
"Healthier cows live longer, produce more milk, and require less medical intervention.”
Petra Grabnar Rogers, Farm Veterinary Surgeon at Delaware Vets, an IVC Farm practice in Somerset, said: "The cow signals training has made a noticeable difference for our farmers.
"Being able to spot early signs of distress or health issues before they become bigger problems will help our farmers reduce vet visits and improve overall herd health.
"It's a simple yet effective approach that we hope will have a positive impact on the productivity of our farm clients."
IVC says that whilst this methodology is known in the UK, opportunities to receive formal training have traditionally been limited and it is the first corporate group to provide widespread cow signals training to all its farm vets.
Nutramega contains omega-3 fatty acids, specifically EPA and DHA, which the company says are critical for the overall health of animals, with many health benefits, including joints & mobility, skin & coat, heart health, the kidneys and brain health.
Nutramega comes in two sizes, 100ml and 200ml, with prices starting from £20.00.
Pet Ready LifeStages are health chews designed to provide daily support for puppies, adult dogs and senior dogs.
Each LifeStage product comes in 30 and 90 chew packets and prices range from £19.99 to £34.99.
www.nutravet.co.uk
The company says farmers should be vaccinating their flocks to help protect the cohort of ewes that missed last year’s vaccination.
Flock replacements should also be vaccinated this summer ahead of tupping.
Shearlings (one year plus) and older can be vaccinated with Cevac Chlamydia within four months before tupping and no later than four weeks before the rams go in, while ewe lambs can be vaccinated from five months of age.
The vaccine should not be used in pregnant ewes.
Fiona Lovatt BVSc PhD FHEA DSHP DipECSRHM FRCVS from Flock Health Ltd said: “It is really good news to hear that there will be good availability of EAE vaccine this year.
"The lambing season started off with some disappointing news for some farmers who were not able to vaccinate last year as they faced EAE abortions.
"We are emphasising to these farmers and others that it is essential that the youngest two years of the ewes are vaccinated before next tupping to ensure that the cohort that missed last year’s vaccination are fully covered.”
https://ruminants.ceva.co.uk.
The survey is part of an initiative to develop a 'roadmap' for what needs to happen to support veterinary teams to deliver contextualised care and shared decision-making.
The survey will be used alongside interviews with people in a range of roles in the veterinary sector, including veterinary receptionists and practice managers, to gather insights about what makes it easier or more difficult to practise contextualised care and what could help support its delivery.
Pet owners will also be surveyed and invited to focus groups to understand what matters most to them when making decisions about their pets’ health, and what would help them to feel supported to decide the veterinary care that is right for them and their pet.
Sally Everitt, Clinical Lead – Evidence at RCVS Knowledge, said: “Although the term contextualised care is now being widely used, and a requirement to practise contextualised care is included in the RCVS Guidance for veterinary surgeons and veterinary nurses, there is little information available on how contextualised care is most effectively delivered in practice.
"Our research aims to address a gap in the evidence about what the barriers and enablers are and what needs to change to support veterinary teams to deliver contextualised care.”
The survey is open to veterinary surgeons currently in clinical practice in the UK working with dogs and cats.
The survey can be accessed here until 17th April 2025: https://survey.alchemer.eu/s3/90806393/rcvskresearchprofessionals
The new gel is made from natural resin combined with zinc salts which NoBACZ says provides both physical and microbial protection.
NoBACZ says that unlike water-based gels and sprays, including aerosols, that dilute in water and wash away, Ambugreen’s natural resin is hydrophobic which improves contact times between the product and the skin in wet conditions.
The gel barrier can be used anywhere on the skin where a bandage or spray has conventionally been used for protection, such as the management of lameness and to protect sore skin in livestock and to manage udder cleft issues in cows.
Ambugreen also offers fly protection and is suitable for use on all livestock, including copper-sensitive sheep breeds.
Dr David Charles, veterinary surgeon and international business development manager at NoBACZ Healthcare, said: “Ambugreen provides farmers with next generation protection for their livestock and is the perfect antibiotic-free tool to help protect wounds from bacterial ingress from the environment; enhancing the health and welfare of animals whilst preventing economic losses.”
Laura Donovan, veterinary surgeon and partner at Nantwich Farm Vets, adds: “We were lucky enough to have trialled Ambugreen with our dairy clients who have successfully used the gel barrier for udder cleft dermatitis and were very pleased with the results.”
www.nobacz.com
CVS says it believes the phone-based resource is a first in the profession.
It contains the ‘kennel side’ veterinary guidelines, notes and charts that clinicians would need to refer to in day-to-day companion animal practice.
It also includes clinical guidelines, anaesthesia, diagnostic imaging, dentistry and toxicology sections, along with an antibiotic guide.
CVS says it hopes the breadth of information in the MiGuide will improve and speed clinical decision-making, making recommendations to clients easier - and ultimately improving patient outcomes.
The hub is the brainchild of Alan Johnson, Regional Clinical Lead at CVS.
He said: “Every day in practice is different.
"You regularly have to do things you have not done for a while.
"So you either have to recall how to do them or spend time looking them up.
"This can be especially difficult when you are looking for very specific information which is buried in a textbook.
“I wanted to consolidate the key clinical information that every colleague needs every day - all in one location.
"I wanted to make information easy to find at a few clicks.
"And I wanted vets and nurses to have this information in their pocket – to refer to if the need arose.
“We hope our new portal is helpful and supportive – and makes daily practice smoother for our vets and nurses.
"And we hope that it improves and speeds up clinical decision-making to provide the best care for our patients.”
In addition to the postings below the notes for SAMSOC AGM are now avalaible in the WIKI section
Fabio Procoli DMV MRCVS, Senior Clinical Training Scholar in Small Animal Internal Medicine RVC
The Royal Veterinary College
As part of the LUPA initiative ( http://www.eurolupa.org ), the Royal Veterinary College, University of London and the Universities of Manchester and Uppsala are collaborating to investigate the genetic...
Exocrine Pancreatic insufficiency (EPI) Treatment Study Aran Mas DVM MRCVS P-J.M.Noble BSc BVM&S PhD MRCVS, A.J.German BVSc PhD CertSAM DipECVIM-CA MRCVS
We are currently looking at the predisposition of Birman cats to congenital portosystemic shunts. The project is being run by Angie Hibbert and Professor Tim Gruffydd-Jones at the Feline Centre Bristol
Stijn Neissen RVC
A study is underway to evaluate the efficacy of Protexin Pro-Kolin Enterogenic in conjunction with ronidazole in the treatment of T.foetus in cats with diarrhoea. Referring vets who have diagnosed T.foetus by PCR are asked to contact Professor Danielle Gunn-Moore or Stephanie Lalor at University of Edinburgh Hospital for Small Animals using the contact details below to discuss enrolment of cats into the study.Tel. 0131 650 7650Email. slalor@staffmail.ed.ac.uk
See attached document for details of BMUS meeting in Brighton which has a veterinary stream
The 2011 AGM meeting minutes have now been uploaded to the media section of the SAMSoc website on vetsurgeon.org
Alex Gough
Dear Colleagues,
We are conducting a survey of veterinary surgeons to try and establish some baseline facts about the treatment of canine lymphoma. We would be most grateful if you would complete the following questionnaire.
The questionnaire is short and simple and should take you no more than 10 minutes to complete. Needing no specific case details, it does not require you refer to clinical records. Furthermore it requires no case follow up at all. If you prefer you can save your responses and return to the survey later, though it is very short.
http://www.smart-survey.co.uk/v.asp?i=37382vpylk
Many thanks indeed in anticipation of your help
Yours faithfully
Christopher Saul, BVetMed CertSAM MRCVS, Cranmore Veterinary Services and Chestergates Referral Hospital
Just a reminder of research projects by our members that are ongoing. Full details can be found in the wiki on the group homepage:
Diabetes Treatment Survey for vets, nurses and owners
Primary Investigator Contact Info:
Stijn Niessen
Department of Veterinary Clinical Sciences,
Royal Veterinary College,
University of London, UK
sniessen@rvc.ac.uk
Genetic Basis of Endocrine Disease in Dogs
Further details can be obtained from:
Brian Catchpole BVetMed PhD MRCVS
Senior Lecturer in Veterinary Immunology
Dept. of Pathology & Infectious Diseases
Royal Veterinary College
Hawkshead Lane,
N. Mymms
Herts AL9 7TA
Tel: +44 (0)1707 666388
Fax: +44 (0)1707 666483
Email: bcatchpole@rvc.ac.uk
Congenital PSS in Birman Cats - DNA Project
Angie Hibbert BVSc CertSAM DipECVIM-CA MRCVS
Feline Centre
University of Bristol
Langford
Exocrine Pancreatic insufficiency (EPI) Treatment Study
Aran Mas DVM MRCVS
P-J.M.Noble BSc BVM&S PhD MRCVS,
A.J.German BVSc PhD CertSAM DipECVIM-CA MRCVS
If you have a suitable case and would like to discuss enrolment on the trial, please do not hesitate to contact us (telephone 0151 795 6100, vetinmed@liv.ac.uk)
Efficacy of masitinib in dogs with steroid-resistant inflammatory bowel disease
cic@rvc.ac.uk
Fabio Procoli
Efficacy of Protexin Pro-Kolin Enterogenic in conjunction with ronidazole in the treatment of T.foetus in cats with diarrhoea
Tel. 0131 650 7650
Email. slalor@staffmail.ed.ac.uk
PhotonUVC Vet is a non-contact treatment which emits low dose ultraviolet C light at a targeted area.
Photon Therapeutics says the device kills bacteria, viruses, fungi and other infecting organisms while being safe to host tissues.
Other claimed benefits of the device are that it avoids client compliance issues associated with eye-drops, it eliminates the need for antibiotic eye drops, and it is very simple to learn how to use.
The device costs £4,995.
To explain more about The PhotonUVC Vet, Dr. Simon Dean. MBChB, MSc, FRANZCO, FBCLA Chief Scientific Officer at Photon Therapeutics, and Dr. Mark Leddy BVSc, MBA, CEO, will be delivering a CPD presentation at the Exhibitor Showcase Theatre 3: "5 Amazing Seconds – A New Transformative Treatment for Corneal Infections", on Thursday 14th November at 3pm.
There is also a launch event reception at the stand from 16.15 to 18.15 on Thursday 14 November.
https://photon-therapeutics.com/
The new clinic is led by Marie Kubiak, an RCVS Specialist and diplomate in Zoo and Wildlife Medicine and one of only a small number Specialists that are accredited for reptiles, birds, pet mammals, wildlife, zoo species, fish and invertebrates.
The open day offers a chance to see the new clinic, meet the team, find out how it can support your practice and discuss any challenging cases you have.
Light snacks and drinks will be provided.
RSVP: evolutionexoticsreferrals@gmail.com
https://evolutionexoticsreferrals.co.uk
Evolution Exotics Referrals, Tenbury Road, Cleobury Mortimer, South Shropshire, DY14 0AD
A team of researchers led by Tim Mair, CVS Equine Veterinary Director and Specialist in both Equine Internal Medicine and Equine Soft Tissue Surgery at Bell Equine Veterinary Clinic, will review 100 cases of colitis in adult horses and 100 controls referred to seven equine veterinary hospitals in the UK: five CVS equine veterinary hospitals as well as Rossdales Equine Hospital and University of Liverpool’s equine hospital.
A set of diagnostic tests on blood and faeces will be performed in these cases.
The laboratory tests will include: small redworm serology, culture and PCR of faeces for Salmonella spp, PCR of faeces for Clostridioides difficile and Clostridium perfringens, ELISA of faeces for toxins of C.difficile and C.perfringens, PCR of faeces for coronavirus.
The clinical features, laboratory results, treatments and outcomes will also be recorded.
Tim said: “Acute colitis accounts for around 5% of admissions to referral hospitals.
"And of those who are referred with it, half will not survive but there is very limited evidence available.
"So it’s vital that we build our evidence-base of this life-threatening condition.
"We hope that the outcomes of our new study will lead to a greater understanding of the causes and better inform veterinary treatment of colitis in UK adult horses.”
The Colitis in Adult Horses study is supported by a research grant from CVS, and funding for the small redworm ELISA will be given from Austin Davis Biologics.
The study started at the beginning of 2024 and the first horses have been recruited.
The results of the study are expected to be published in 2025.
Andy, who was previously the Junior Vice Chair of the association, has been a member of BVOA for over 25 years, during which time he's been instrumental in organising scientific meetings and starting the popular BVOA discussion forum.
He is an RCVS and ECVS Specialist and in 2017 was made a Fellow of the RCVS for meritorious contributions to clinical practice.
He has taught numerous surgical residents and is widely published in many areas of orthopaedic surgery.
In 2023 he opened the Moores Orthopaedic Clinic, a dedicated orthopaedic-only referral clinic near Basingstoke in Hampshire.
Andy said: “It’s a great honour to take on the role of chairman for an organisation that I am so fond of.
“I am passionate about education and have taught, lectured and published widely.
"In my role at the Moores Orthopaedic Clinic I am always happy to discuss cases and assist colleagues as much as possible.
"I truly believe sharing knowledge is essential to successful patient outcomes, and BVOA allows this in numerous ways.
"My thanks go out to the rest of the BVOA committee for continuing to ensure we have a strong and vibrant Association, especially to Mark Bush my predecessor and to Sarah Girling who has left the committee this year after serving as Senior Vice Chair.”
All veterinary professionals with an interest in orthopaedics are welcomed and encouraged to join BVOA.
https://bvoa.co.uk/
Programme attached including details of how to register
Early bird registration deadline is 3 March for the SAMSoc pre-BSAVA meet. Please register soon!
Visit www.samsoc.org for details.
Entries for our case report competition are invited before Friday 1 March 2019.